Compare NBIX & CNH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | CNH |
|---|---|---|
| Founded | 1992 | 1842 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 20.1B |
| IPO Year | 1996 | 2013 |
| Metric | NBIX | CNH |
|---|---|---|
| Price | $167.43 | $11.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 18 |
| Target Price | ★ $208.11 | $14.94 |
| AVG Volume (30 Days) | 1.3M | ★ 15.9M |
| Earning Date | 11-02-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 0.84% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 5.26 | 0.14 |
| Revenue | $161,626,000.00 | ★ $18,095,000,000.00 |
| Revenue This Year | $39.52 | N/A |
| Revenue Next Year | $14.81 | $6.45 |
| P/E Ratio | ★ $32.28 | $85.86 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $122.14 | $9.12 |
| 52 Week High | $186.12 | $14.46 |
| Indicator | NBIX | CNH |
|---|---|---|
| Relative Strength Index (RSI) | 66.05 | 49.49 |
| Support Level | $152.67 | $10.02 |
| Resistance Level | $169.57 | $14.31 |
| Average True Range (ATR) | 5.47 | 0.56 |
| MACD | 2.07 | 0.11 |
| Stochastic Oscillator | 80.70 | 46.81 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
CNH Industrial is the world's second largest manufacturer of agricultural machinery (82% of industrial net sales) as well as a major player in construction equipment (18% of industrial net sales). Its Case and New Holland brands have served farmers for generations. Geographically, agricultural sales are 40% in North America, 32% in Europe, the Middle East, and Africa, 18% in South America, and 10% in Asia-Pacific. CNH's products are available through a robust independent dealer network, which includes over 2,600 dealer and distribution locations and reach into 164 countries. The construction business leverages over 400 dealers. The company's captive finance arm provides retail financing to its customers and wholesale financing to dealers to maintain inventory, thereby supporting sales.